ArticleClinical chemistry and laboratory medicine2026
Establishing reference intervals for high-sensitivity cardiac troponin T in neonates and infants.
Article in Clinical chemistry and laboratory medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of DeepSeek-R1 for Ophthalmic Diagnosis and Reasoning: A Comparison with OpenAI o1 and o3.Journal of medical systems · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesHigh-sensitivity cardiac troponin T (hs-cTnT) is used in pediatric healthcare to diagnose and assess the prognosis of various cardiac diseases, such as acute myocarditis, congenital heart disease, dilated cardiomyopathy, and heart failure. However, the standardized age-related reference intervals, 99th percentile cut-offs, and clinical guidelines are currently unavailable, especially in newborns and infants, making interpreting this biomarker challenging.
methodsResidual serum samples were collected from 1,047 pediatric subjects with no cardiovascular disease, including 145 neonates and 902 infants. The concentrations of hs-cTnT were analyzed using Roche's Elecsys Troponin T hs assay. The age-related 99th percentile cut-offs with 90 % confidence intervals (CIs) of hs-cTnT were established.
resultsSubjects were divided into age subgroups as follows: newborns (0-30 days, n=142), infants aged 1 month (31-60 days, n=223), 2 months (61-90 days, n=152), 3-4 months (91-150 days, n=211), 5-6 months (151-210 days, n=149), and 7 months-1 year (211-365 days, n=149). Serum hs-cTnT concentrations were highest during the first month of life and progressively declined in a year. The 99th percentile cut-offs of hs-cTnT concentration in each group were as follows: 114 (90 % CI: 114-114), 65.6 (63.7-66.1), 55.2 (54.4-55.2), 30.4 (29.1-30.9), 23.5 (22.1-23.5), 12.7 (12.4-12.7) ng/L. The 97.5th percentile cut-offs for each group were 109.4 (105.2-114), 62.5 (60.5-63.9), 52.3 (50.3-54.4), 29 (28.5-29.1), 20.5 (19.2-23.4), and 12 (12-12.1) ng/L.
conclusionsThis study aimed to provide reliable pediatric reference values for hs-cTnT based on a population of well-child children. These reference intervals and 99th percentile cut-offs will inform clinical decisions in the pediatric cardiology setting.
Indexed as
Identifiers
40991514What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.